FDA allows Vaccinex to begin VX15/2503 Phase 1 trial
VX15/2503 is a humanized antibody that blocks the activity of semaphorin 4D (SEMA4D). Vaccinex plans to initiate a second trial of VX15/2503 for MS later this year. Vaccinex
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China.